Testosterone replacement therapy: fundamentals, evidence, and monitoring

Testosterone replacement therapy (TRT) is a medical treatment that raises testosterone levels in men whose bodies do not produce enough of it, a condition generally called male hypogonadism. It is a diagnosis-driven treatment, not a general enhancement intended for men with normal testosterone levels who want higher energy or muscle gain. The Endocrine Society's clinical practice guideline recommends diagnosing hypogonadism only in men with both consistent symptoms and unambiguously low testosterone levels confirmed on morning blood draws, specifically recommending against basing a diagnosis on a single test or on symptoms alone [1]. This distinction matters because testosterone naturally fluctuates with time of day, sleep, illness, and stress, so one borderline reading does not establish a diagnosis.

The symptoms associated with hypogonadism include reduced libido, erectile dysfunction, fatigue, low mood, reduced muscle mass, increased body fat, and reduced bone density, but none of these symptoms is specific to low testosterone; they overlap with many other common conditions, including depression, sleep disorders, and thyroid dysfunction. This is part of why the Endocrine Society's guideline calls for both a consistent symptom pattern and clearly low, repeated laboratory values rather than either one alone [1].

Once a diagnosis is established, injectable testosterone esters, such as testosterone cypionate or enanthate, are a common first-line option because they have a long track record and are relatively inexpensive, typically administered as an injection every one to two weeks depending on the specific regimen a clinician selects, though more frequent, smaller injections are sometimes used to reduce peak-to-trough fluctuation. Topical gels, patches, longer-acting injectable esters, and subcutaneous pellets are alternative delivery methods with different absorption profiles, monitoring considerations, and practical tradeoffs, such as the risk of transferring gel-based testosterone to a partner or child through skin contact. The specific formulation and dosing interval is a decision made with a prescribing clinician based on the individual's labs, goals, and tolerance, not a generic recommendation that applies uniformly.

The strongest and most consequential recent evidence on TRT concerns cardiovascular safety. Earlier, smaller observational studies had raised concern that testosterone therapy might increase cardiovascular risk, which left the field without a clear answer for years. The TRAVERSE trial, a large randomized, double-blind, placebo-controlled noninferiority trial published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with hypogonadism and existing or elevated cardiovascular risk, and found that testosterone-replacement therapy was noninferior to placebo on the primary composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke [2]. This is Strong Human Evidence, given the trial's size, randomized design, and specific focus on cardiovascular risk in exactly the population where the earlier concern existed. The same trial did find a higher incidence of non-fatal arrhythmias, including atrial fibrillation, in the testosterone group, along with signals for venous thromboembolism and fractures reported in related TRAVERSE sub-studies, findings that complicate a simple 'safe' or 'unsafe' label and argue for ongoing monitoring rather than either alarm or complacency.

The benefits reported in men with confirmed hypogonadism, when treatment is monitored appropriately, include improvements in libido, sexual function, mood, and, combined with resistance training, lean muscle mass, findings that appear consistently enough across trials referenced in the Endocrine Society guideline to be described as Moderate to Strong Human Evidence specifically in men who meet diagnostic criteria [1]. These benefits are not established for men with normal testosterone levels seeking enhancement beyond their baseline, a population and use case the Endocrine Society guideline explicitly does not endorse [1].

TRT produces predictable physiological effects beyond its intended benefit that require monitoring rather than being ignored. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, the signaling loop that normally drives the testes to produce both testosterone and sperm; this commonly causes testicular volume reduction and a drop in sperm production, sometimes to complete absence, because the pathway that stimulates natural production has been shut down by the external supply [3]. A review in Therapeutic Advances in Urology describes this suppression as a predictable, mechanism-based consequence of testosterone therapy, rather than an idiosyncratic side effect limited to some individuals [3]. Hematocrit, a measure of red blood cell concentration, tends to rise on testosterone therapy and requires monitoring because excessive elevation increases blood viscosity and clotting risk, which is one of the parameters the Endocrine Society guideline specifically recommends tracking [1]. Other recognized effects include acne, potential worsening of sleep apnea, and, in men genetically predisposed to it, acceleration of male pattern hair loss.

Fertility deserves specific attention because the suppression described above is not automatically reversible on a convenient timeline, and it is frequently underappreciated before treatment starts. For men who wish to preserve fertility while on TRT, human chorionic gonadotropin (HCG), which mimics the pituitary signal that testosterone therapy suppresses, is one option clinicians use concurrently with testosterone to help maintain testicular function and sperm production, and clomiphene citrate is another option used in a different way for men managing hypogonadism with a fertility goal [3]. The Therapeutic Advances in Urology review notes that recovery of spermatogenesis after stopping testosterone therapy is common but not universal or immediate, with recovery times varying by age, duration of therapy, and baseline testicular function, and it specifically recommends that sperm cryopreservation be discussed before starting TRT or anabolic-androgenic steroids as a safeguard [3]. This is a conversation to have with a prescribing clinician before starting therapy, not something to work out retroactively once fertility becomes a concern.

Ongoing monitoring is a structural part of TRT, not an optional add-on. The Endocrine Society guideline recommends assessing testosterone levels, hematocrit, and prostate-specific antigen (PSA) at defined intervals, more frequently in the initial months of therapy and less often once levels have stabilized, along with periodic reassessment of symptoms and any relevant lipid or metabolic values [1]. Because TRT is generally a long-term or indefinite therapy once started, given that natural production frequently does not reliably resume to its prior level after suppression, monitoring is not a phase to get through but a continuing part of the treatment relationship with a prescribing clinician.

Different delivery formulations also carry different practical monitoring burdens worth understanding at a conceptual level, even though the choice itself is clinical. Injectable esters produce a rise-and-fall pattern in blood levels between doses, with the size of that swing depending on the specific ester and injection frequency, which is one reason more frequent, smaller injections are sometimes used to flatten the curve. Transdermal gels aim for steadier daily levels but introduce a real transfer risk to partners, children, or pets through skin-to-skin contact if application-site precautions are not followed. Subcutaneous pellets provide months of exposure from a single procedure but cannot be adjusted or removed easily if the dose turns out to be too high or too low, which trades flexibility for convenience in a way that suits some patients and not others. None of these tradeoffs makes one formulation universally superior; they are inputs to a decision made jointly with a prescriber based on the individual's goals, tolerance, and practical constraints.

Lifestyle factors interact with testosterone physiology in ways that are worth understanding even though they do not replace a medical evaluation. Sleep restriction, obesity, and heavy alcohol use are each independently associated with lower testosterone levels and can also affect how the body processes and responds to therapy once started; obesity in particular increases the conversion of testosterone to estrogen through a process called aromatization. None of this means lifestyle change is a substitute for treatment in a man who meets diagnostic criteria for hypogonadism, but it is relevant context a clinician may weigh when evaluating symptoms and lab values, and it is a reasonable area to discuss during that evaluation rather than a side issue.

Evidence quality and limitations: the diagnostic criteria and monitoring recommendations described here come from a formal, peer-reviewed clinical practice guideline representing Strong Human Evidence and expert consensus [1]. The cardiovascular safety findings are Strong Human Evidence from a large randomized trial specifically designed to answer that question [2], though the trial population, men with existing or elevated cardiovascular risk, means its findings may not generalize identically to men without that risk profile who are otherwise candidates for therapy. Fertility-related findings are Moderate Human Evidence, drawn from clinical reviews describing consistent mechanisms and treatment approaches rather than large randomized outcome trials specific to fertility preservation strategies [3]. None of this article constitutes a treatment recommendation for any individual; the decision to start, adjust, or stop TRT, and the specific monitoring schedule and thresholds used, is a clinical decision between a patient and a qualified prescriber familiar with that patient's full history.